Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003

Quoin Pharmaceuticals, Ltd.

IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.
Pruritus (itch) score reduced from 5 to 1; patient stopped all antihistamines, glucocorticoids, and antivirals.
Patient now experiences zero nightly sleep disturbances for first time; no adverse events reported.
First pediatric patient data from ongoing Investigator Pediatric Netherton Syndrome study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.